米特拉基宁对P-糖蛋白载体的调节作用
Muhammad Asyraf Abduraman1, Azimah Amanah2, Shahrul Bariyah Sahul Hamid1
1Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Kepala Batas, Pulau Pinang, Malaysia.
The Journal of pharmacy and pharmacology
|November 14, 2024
概括
在 kratom 中发现的米特拉基宁抑制了 P-glycoprotein (P-gp) 的运输. 这种相互作用可能会导致危险的药物-草药相互作用和神经毒性,当 kratom 与其他药物一起使用时.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
背景情况:
- Kratom (Mitragyna speciosa) 是一种含有mitragynine的娱乐性药物.
- 甲基尼因经常与其他药物一起被发现,这引发了安全问题.
- P-glycoprotein (P-gp) 是一种大脑载体,其功能可以被药物改变,可能导致神经毒性.
研究的目的:
- 为了研究米特拉基宁对P-gp调节的影响.
- 评估与米特拉金因与P-gp相互作用相关的潜在神经毒性.
主要方法:
- 使用人类大脑毛细体内皮细胞 (hCMEC/D3) 进行P-gp调节研究.
- 采用分子对接,动态模拟和运输试验来分析米特拉基宁-P-gp相互作用.
- 在PC-12细胞中使用血脑屏障模型和PCR阵列评估神经毒性.
主要成果:
- 米特拉基尼因通过与其核酸结合域结合来抑制P-gp运输.
- 非有毒度的米特拉金因增强了内皮细胞的透性.
- 甲基尼因暴露导致PC-12细胞中出现神经毒性迹象.
结论:
- 米特拉基宁作为P-gp抑制剂起作用.
- 同时使用kratom和P-gp基质可能会导致显著的药物-草药相互作用.
- 临床上显著的神经毒性的潜力存在于联合使用.
相关概念视频
Carrier-Mediated Transport
279
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
279
Drugs Affecting Neurotransmitter Release or Uptake
954
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
954
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Opioid Receptors: Overview
538
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
538
Nonlinear Pharmacokinetics: Role of Transporters
35
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
35
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K


